USPTO serial 99624878
SOLEY
Reviewed by CopyMark Law Group
Status 802
- Filing date
- Status date
- Registration date
- —
- Examiner
- MICKLEBURGH, LINDA BOHANNON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SOLEY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA, US
San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alyssa M. Worsham
Alyssa M. Worsham WILSON SONSINI GOODRICH & ROSATI650 Page Mill RoadPalo Alto, CA 94304United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological, medicinal and pharmaceutical preparations for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, neuromuscular, central nervous system, rare muscle, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, genetic, blood, inflammatory, psychiatric, and immune system related diseases and disorders; therapeutic pharmaceuticals for the prevention and treatment of viral, infectious, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, neuromuscular, central nervous system, rare muscle, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, genetic, blood, inflammatory, psychiatric, and immune system related diseases and disorders | ACTIVE | — |
| 009 | Downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; downloadable computer software, namely, software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning for use in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; downloadable computer software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; downloadable computer software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; downloadable computer software for analyzing and generating insights from the sensing and response capabilities of cells for use by biotechnology and pharmaceutical companies; downloadable computer software for decoding cellular language for use by biotechnology and pharmaceutical companies; downloadable computer software for stain-free brightfield time-lapse imaging of cells for use in medical research | ACTIVE | — |
| 042 | Drug discovery services; pharmaceutical research and development services; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning for use in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning for use in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; providing an online non-downloadable computer software platform for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, featuring software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; software as a service (SAAS) services featuring software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; providing an online non-downloadable computer software platform for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; providing an online non-downloadable computer software platform for analyzing and generating insights from the sensing and response capabilities of cells for use by biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for analyzing and generating insights from the sensing and response capabilities of cells for use by biotechnology and pharmaceutical companies; providing online non-downloadable computer software for decoding cellular language for use by biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for decoding cellular language for use by biotechnology and pharmaceutical companies; providing online non-downloadable computer software for stain-free brightfield time-lapse imaging of cells for use by biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for stain-free brightfield time-lapse imaging of cells for use by biotechnology and pharmaceutical companies; preclinical drug discovery services used for identifying, designing, and optimizing chemical compounds; pharmaceutical product evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery via software using artificial intelligence; preclinical pharmaceutical drug development services used for identifying, designing, and optimizing chemical compounds; pharmaceutical evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing chemical series and chemical compounds via software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computational modeling, high-throughput screening, medicinal chemistry, biology, pharmacology, computerized simulations, virtual screening, and generative chemistry; providing an online searchable database in the fields of pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of pharmaceutical preparations, scientific development of new uses for pharmaceutical compounds, and scientific technical research; scientific research and development for scientific purposes, namely, forecasting the use of molecules as drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, molecular screening, cellular screening, phenomics, genetics, genomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; drug discovery services, namely, phenotypic screening services for discovering novel molecules to develop into drug compounds; medical and scientific research, namely, conducting clinical trials for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2026 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 22, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 22, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 16, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 24, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 21, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 2, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 24, 2026 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| May 24, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 30, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 30, 2026 | NWAP | NEW APPLICATION ENTERED | — |